Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care?


Journal

Urology
ISSN: 1527-9995
Titre abrégé: Urology
Pays: United States
ID NLM: 0366151

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 11 04 2023
revised: 26 05 2023
accepted: 03 07 2023
medline: 23 10 2023
pubmed: 20 7 2023
entrez: 19 7 2023
Statut: ppublish

Résumé

Patients with advanced penile squamous cell cancer have a poor prognosis and can benefit from early palliative care consultation. We built a model to identify those patients most likely to benefit. Patients with penile squamous cell cancer undergoing inguinal lymph node dissection were identified from the National Cancer Database (NCDB) and a multi-institutional international dataset (INT). A multivariable Cox proportional hazards model for overall survival (OS) was developed using the NCDB and applied to the INT dataset. Parameters were used to make receiver operating characteristic (ROC) curves. ROC-related criteria were optimized to identify a predictive probability cut point and dichotomize patients from INT into risk groups for limited OS of <6 and <12 months. NCDB had 860 deaths; 105 (5%) at 6 months and 296 (15%) at 12 months. INT had 257 deaths; 56 (8%) at 6 months and 124 (18%) at 12 months. Limited OS was associated with older age, greater T and N stage, and fewer lymph nodes removed. Optimized ROC criteria using the OS <6 months curve best dichotomized INT patients into high-risk group with median OS of 24 months (95% CI 18-34) and low-risk group with median OS of 174 months (95% CI 120-NE). We developed a simple model that could be used as a screening tool for early palliative care referral.

Identifiants

pubmed: 37467807
pii: S0090-4295(23)00590-3
doi: 10.1016/j.urology.2023.07.006
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

176-181

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no conflict of interest to declare.

Auteurs

Lee A Hugar (LA)

Lexington Medical Center, Lexington Urology, Columbia, SC.

Taylor C Peak (TC)

H Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL. Electronic address: Taylor.Peak@moffitt.org.

Mahrukh Naqvi (M)

H Lee Moffitt Cancer Center, Department of Biostatistics and Bioinformatics, Tampa, FL.

Youngchul Kim (Y)

H Lee Moffitt Cancer Center, Department of Biostatistics and Bioinformatics, Tampa, FL.

Marco Bandini (M)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Filippo Pederzoli (F)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Laura Marandino (L)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Maarten Albersen (M)

University Hospitals Leuven, Leuven, Belgium.

Eduard Roussel (E)

University Hospitals Leuven, Leuven, Belgium.

Yao Zhu (Y)

Fudan University Shanghai Cancer Center, Shanghai, China.

Ding-Wei Ye (DW)

Fudan University Shanghai Cancer Center, Shanghai, China.

Antonio A Ornellas (AA)

Hospital Mário Kröeff and Brazilian Cancer Institute, Rio de Janeiro, Brazil.

Mario Catanzaro (M)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Oliver W Hakenberg (OW)

University Hospital Rostock, Rostock, Germany.

Axel Heidenreich (A)

Universitätsklinikum Köln, Köln, Germany.

Friederike Haidl (F)

Universitätsklinikum Köln, Köln, Germany.

Nick Watkin (N)

St. George's University Hospitals, NHS Foundation Trust, London, UK.

Michael Ager (M)

St. George's University Hospitals, NHS Foundation Trust, London, UK.

Alberto Briganti (A)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Roberto Salvioni (R)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Nicholas H Chakiryan (NH)

Lexington Medical Center, Lexington Urology, Columbia, SC.

Francesco Montorsi (F)

Urological Research Institute (URI), Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.

Andrea Necchi (A)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Philippe E Spiess (PE)

H Lee Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH